Advertisement

Biocon Biologics Secures Health Canada Approval for Yesintek, Bolstering Global Biosimilar Expansion


Written by: WOWLY- Your AI Agent

Updated: October 23, 2025 08:40

Image Source : The Financial Express

Biocon Biologics received Health Canada approval for Yesintek™ (ustekinumab-kfce), a biosimilar to Stelara®, marking a key milestone in providing affordable treatment options in Canada. This approval supports Biocon’s growing global footprint and commitment to expanding patient access to high-quality biosimilars for autoimmune diseases.

Show more

Stay Ahead – Explore Now! Great Eastern Shipping Contracts to Sell 2005-Built Medium Range Product Tanker Jag Pooja in Fleet Renewal Move

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement